Skip to main content
TipRanks
Go Ultimate75% OFF

Atara Biotherapeutics (ATRA) AI Stock Analysis

1,211 Followers
ATRA

Atara Biotherapeutics

(NASDAQ:ATRA)

Select Model
Rating:42Neutral
Price Target:$8.00â–²(3.90% Upside)
Action:reiterated
Date:11/11/26

ATRA scores low primarily due to weak financials (steep revenue drop, very large losses, ongoing cash burn, and negative equity). Technicals also lean bearish with the stock below key moving averages and a negative MACD, while valuation provides limited support given losses (negative P/E) and no dividend yield.

Positive Factors
Off-the-shelf T-cell platformAn allogeneic, off-the-shelf platform can support more standardized development and broader deployment than individualized cell therapies. Atara’s focus across oncology and serious diseases provides a durable technology base that may support multiple candidates and partnering opportunities over time.
Negative Factors
Persistent cash burnSustained negative operating and free cash flow indicates that the current business does not yet fund its own activities. Continued cash consumption increases dependence on financing, makes execution sensitive to capital access, and can restrict investment in clinical and regulatory programs.

Atara Biotherapeutics (ATRA) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%40%ATRA-42.79%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$78.45M
Dividend Yield
―
Average Volume (3M)
36.32K
Price to Earnings (P/E)
-7.6
Beta (1Y)
0.87
Revenue Growth
-97.39%
EPS Growth
-155.19%
Country
US
Employees
14
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Atara Biotherapeutics Business Overview & Revenue Model

Company Description

Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments fo...

How the Company Makes Money

Atara Biotherapeutics primarily generates revenue through collaboration and license arrangements rather than recurring product sales (as a clinical-stage biotech, it generally does not have sustained commercial revenue). Key revenue streams include:...

Atara Biotherapeutics Financial Statement Overview

Summary

Financial performance is very weak: sharp TTM revenue decline (-35.99%), deeply negative profitability (net margin -533%), negative operating/free cash flow (-$13.0M), and negative equity (-$37.9M) that increases financing and dilution risk. Modest debt helps slightly, but does not offset the overall strain.

Income Statement

28Negative

Balance Sheet

22Negative

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.96M120.77M128.94M8.57M63.57M20.34M
Gross Profit3.28M99.56M107.93M-313.00K-206.42M-261.66M
EBITDA-12.61M38.63M-75.75M-266.00M-222.26M-330.75M
Net Income-14.61M32.69M-85.40M-276.13M-228.30M-340.14M
Balance Sheet
Total Assets18.61M20.23M109.10M165.50M376.42M468.13M
Cash, Cash Equivalents and Short-Term Investments9.92M8.48M42.50M51.73M242.82M371.07M
Total Debt9.57M52.80M43.83M57.87M71.70M28.27M
Total Liabilities56.51M58.74M206.38M264.74M249.78M188.51M
Stockholders Equity-37.90M-38.50M-97.28M-99.23M126.64M279.61M
Cash Flow
Free Cash Flow-12.99M-50.94M-68.96M-194.20M-274.62M-231.10M
Operating Cash Flow-12.99M-50.94M-68.72M-192.98M-270.43M-220.52M
Investing Cash Flow2.65M18.15M8.62M123.87M202.96M22.26M
Financing Cash Flow8.65M16.10M59.28M2.01M53.08M103.94M

Atara Biotherapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price7.70

Price Trends

50DMA8.94Negative
100DMA9.03Negative
200DMA7.83Negative

Market Momentum

MACD-0.31Positive
RSI38.45Neutral
STOCH41.19Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATRA, the sentiment is Negative. The current price of 7.70 is below the 20-day moving average (MA) of 8.42, below the 50-day MA of 8.94, and below the 200-day MA of 7.83, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 38.45 is Neutral, neither overbought nor oversold. The STOCH value of 41.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATRA.

Atara Biotherapeutics Risk Analysis

Atara Biotherapeutics disclosed 76 risk factors in its most recent earnings report. Atara Biotherapeutics reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Risks Related to Ownership of Our Common StockQ2, 2026
2.General Risk FactorsQ2, 2026
3.Risks Related to Our Financial Results, Capital Needs, and Review of Strategic AlternativesQ2, 2026

Atara Biotherapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ATRA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SRZNSRZN53Neutral$602.54M-0.72228.00%―192.12%-100.54%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
MGNXMGNX47Neutral$140.60M-2.72-142.22%―-11.07%30.92%
ZNTLZNTL44Neutral$167.05M-0.89-75.82%―-100.00%7.45%
ATRAATRA42Neutral$78.45M-7.6238.79%―-97.39%-155.19%
TCRXTCRX38Underperform$10.89M-0.18-140.75%―-38.43%20.89%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%400%ATRAMGNXZNTLSRZNTCRXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ATRA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ATRAAtara Biotherapeutics Inc7.70-5.40-41.22%
MGNXMacroGenics Inc2.200.6945.70%
ZNTLZentalis Pharmaceuticals Inc1.700.3828.79%
SRZNSurrozen, Inc.31.6118.81146.95%
TCRXTscan Therapeutics, Inc.0.16-0.81-83.51%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026